Semaglutide
Molecular Research Profile · Target purity > 99.0% · Half-life ~7 days
Single-agonist GLP-1 receptor agonist. The foundational compound in the incretin mimetic class, with extensive clinical characterization and well-established purity benchmarks in research settings.
Mechanism of Action
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1, engineered with two key modifications: an amino acid substitution at position 8 (α-aminoisobutyric acid for alanine) conferring DPP-IV resistance, and a C18 fatty diacid chain at lysine-26 promoting albumin binding for extended half-life (~7 days). These modifications extend the plasma half-life from ~2 minutes (native GLP-1) to approximately 165 hours.
At the GLP-1 receptor, semaglutide activates cAMP-PKA signaling in pancreatic β-cells (glucose-dependent insulin secretion), suppresses glucagon release from α-cells, and reduces hepatic gluconeogenesis. In the central nervous system, it activates GLP-1 receptors in the arcuate nucleus and area postrema, producing satiety signaling and reduced food intake. Gastric emptying is dose-dependently delayed, contributing to postprandial glycemic control.
Compared to tirzepatide (dual GIP/GLP-1) and retatrutide (triple GIP/GLP-1/GCG), semaglutide is a purer research tool for isolating GLP-1-specific effects. Its well-characterized binding kinetics and extensive clinical data make it the standard reference compound for GLP-1 receptor agonism studies.
Research History & Context
Semaglutide was developed by Novo Nordisk, building on the liraglutide platform. Phase 3 SUSTAIN trials (2016–2018) for type-2 diabetes and STEP trials (2018–2021) for obesity demonstrated mean body-weight reductions of approximately 15% at 68 weeks. Clinical authorization was granted in 2017 (Ozempic, T2D) and 2021 (Wegovy, obesity).
As a research peptide, semaglutide is among the most analytically characterized GLP-1-family compounds available from independent suppliers. Its widespread clinical use means HPLC reference standards are readily available, and purity expectations (>99.0%) are well-calibrated against pharmaceutical-grade benchmarks.
Storage & Handling
Store lyophilized semaglutide at -20°C in a dry, dark environment. Stability exceeds 24 months. The fatty-acid moiety makes semaglutide more hydrophobic than tirzepatide; ensure complete dissolution during reconstitution (swirl for 60–90 seconds rather than agitate).
After reconstitution with bacteriostatic water, semaglutide should be refrigerated at 2–8°C and used within 28 days. The peptide forms multimers (primarily hexamers) in solution at the zinc-containing concentrations found in pharmaceutical formulations; research-grade material typically forms dimers and tetramers at standard reconstitution concentrations, which does not affect receptor binding.
Reconstitution & Research Dosing
For Semaglutide, the standard laboratory reconstitution is 2.0 ml BAC water for 5mg vial. A typical research study window uses 0.25 - 1.0 mg / week (titration protocol).
For a 5mg semaglutide research vial, add 2.0 ml BAC water (2.5 mg/ml). For micro-dosing protocols, add 5.0 ml BAC water (1.0 mg/ml) to facilitate precise low-volume dosing. The standard weekly research protocol makes semaglutide one of the more convenient GLP-1 peptides — a single reconstituted vial typically covers 4–8 weeks of research.
Use the Reconstitution Calculator for exact syringe units →Explore Related Research Compounds
Research Use Only (RUO): Semaglutide is discussed strictly as an in-vitro laboratory research compound. Nothing on this page constitutes human or clinical administration guidance. Always verify purity through independent third-party HPLC/MS analysis before use.